INTRODUCCIÓN: REVISIÓN CRITICA DEL PROBLEMA

RESULTADOS
kidney failure, and fluorescent AGE (per arbitrary unite) were significant predictors
of morbidity / mortality. In stepwise multivariate analysis SHFS, NT–pro-BNP, and
sRAGE remained significant (Figure 2). Neither serum creatinine nor estimated
glomerular filtration rate reached statistical significance for morbidity and mortality
in multivariate analysis.
TABLE 2. Clinical characteristics of high and low sRAGE groups
Characteristics High sRAGE Low sRAGE P Value
Age (years) 72.6 ± 9.6 67.5 ± 12.8 0.023
Female 35.3% 30.2% 0.579
BMI (Kg/m 2 )
27.7 ± 4.2
28.7 ± 4.5
0.341
Hypertension 56.9% 58.8% 0.841
Dyslipidemia 58.0% 47.1% 0.271
Diabetes
36.5%
35.2%
0.885
NYHA III-IV 32.7% 12.0% 0.013
Ischemic etiology 43.1% 21.2% 0.017
Depressed LVEF
57.4%
66.0%
0.386
eGFR < 60 ml/min 49.0% 30.8% 0.045
Haemoglobin (g/dL) 12.6 ± 1.6 13.6 ± 1.5 0.002
HDL-cholesterol (mg/dL) 40.2 ± 12.8 45.5 ± 21.5 0.152
LDL-cholesterol (mg/dL) 109.8 ± 38.4 115.8 ± 31.9 0.921
Glucose (mg/dL) 127.6 ± 52.9 115.8 ± 31.9 0.178
Glycated haemoglobin 6.7 ± 1.5 5.9 ± 0.9 0.003
Fluorescent AGE (a.u.) 71.1 ± 23.2 63.7 ± 21.7 0.093
NT-proBNP (pg/mL)
SHFS
Treatment
ACEI/ARA-2
Beta-blockers
Diuretics
Statins
Insulin
3097.9 ± 3077.8 2325.4 ± 3418.9 0.288
8.4 ± 5.9 6.2 ± 4.0 0.032
84.6%
83.7%
95.7%
44.9%
17.6%
90.2%
86.5%
88.8%
44.2%
3.8%
0.195
0.686
0.666
0.946
0.024
Death 17.6% 3.7% 0.022
Cardiac events 44.2% 11.1% 0.001
Abbreviations as in Table 1
97